{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:53:23Z","timestamp":1761598403252,"version":"3.44.0"},"reference-count":6,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>\n                  <jats:bold>Overview of:<\/jats:bold> Medicines and Healthcare products Regulatory Agency. Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus. <jats:italic>Drug Safety Update<\/jats:italic> 2021;15:3.<\/jats:p>","DOI":"10.1136\/dtb.2021.000073","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T13:27:15Z","timestamp":1641907635000},"page":"36-36","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Dapagliflozin no longer licensed for type 1 diabetes"],"prefix":"10.1136","volume":"60","member":"239","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"2025082722072374000_60.3.36.1","first-page":"3","article-title":"Dapagliflozin (Forxiga): no longer authorised for treatment of type 1 diabetes mellitus","volume":"15","year":"2021","journal-title":"Drug Safety Update"},{"key":"2025082722072374000_60.3.36.2","unstructured":"Astra Zeneca . Forxiga (dapagliflozin) 5mg should no longer be used for the treatment of Type 1 diabetes mellitus [online]. Available: https:\/\/assets.publishing.service.gov.uk\/media\/619374948fa8f5037ffaa083\/20211102-uk-dhpc-forxiga-T1D-withdrawal.pdf [Accessed 10 Dec 2021]."},{"key":"2025082722072374000_60.3.36.3","unstructured":"European Medicines Agency . Forxiga [online], 2021. Available: https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-forxiga-ws-1344_en.pdf [Accessed 10 December 2021]."},{"key":"2025082722072374000_60.3.36.4","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2019.000081"},{"key":"2025082722072374000_60.3.36.5","first-page":"1","article-title":"SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis","volume":"9","year":"2016","journal-title":"Drug Safety Update"},{"key":"2025082722072374000_60.3.36.6","unstructured":"OpenPrescribing.net, EBM DataLab, University of Oxford . Search GP prescribing data [online], 2021. Available: https:\/\/openprescribing.net\/analyse\/#org=CCG&numIds=0601023AGAAAAAA,0601023AGBBAAAA&denom=nothing&selectedTab=summary [Accessed 10 December 2021]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2021.000073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:07:35Z","timestamp":1756357655000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2021.000073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":6,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2,23]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/dtb.2021.000073"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2021.000073","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2022,1,11]]}}}